The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Hypersensitivity reactions from taxol.
Abstract
Taxol is an antitumor agent in clinical trial that has been shown to have activity against advanced ovarian carcinoma and melanoma. Hypersensitivity reactions (HSRs) have been one of the toxicities observed with administration of this drug. Of 301 patients treated, 32 patients have had definite (27 patients) or possible (five patients) hypersensitivity reactions to taxol. All but one patient had the reaction from the first or second exposure to this agent. Reactions occurred at a variety of doses and were characterized most frequently by dyspnea, hypotension, bronchospasm, urticaria, and erythematous rashes. Thirteen (41%) patients had received premedication designed to prevent such toxicity; nevertheless, they sustained HSRs. Prolonging the drug infusion appears to have somewhat reduced, but not obviated, the risk of HSRs. The cause (taxol itself or its excipient Cremophor EL; Badische Anilin und Soda-Fabrik AG [BASF], Ludwigshafen, Federal Republic of Germany) and the mechanism of these reactions to taxol are unknown. We provide guidelines to prevent or minimize such toxicity and treat reactions if they still occur.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Self-citationPhase I clinical and pharmacokinetic study of taxol.
Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., & Paietta, E. M. (1987) · PubMed · Cited by 455
Self-citationWiernik, P. H., Schwartz, E. L., Einzig, A., Strauman, J. J., Lipton, R. B., & Dutcher, J. P. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1232 · Cited by 275
Self-citationLorenz, W., Reimann, H. J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., & Doenicke, A. (1977) · Agents and Actions · doi:10.1007/bf01964882 · Cited by 219
COMPLEMENT AS A MEDIATOR OF INFLAMMATION
da Silva, W. D., Eisele, J. W., & Lepow, I. H. (1967) · The Journal of Experimental Medicine · doi:10.1084/jem.126.6.1027 · Cited by 197
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Rowinsky, E. K., Burke, P. J., Karp, J. E., Tucker, R. W., Ettinger, D. S., & Donehower, R. C. (1989) · PubMed · Cited by 196
Self-citationSuspected anaphylactic reaction to Cremophor EL.
Dye, D., & Watkins, J. (1980) · BMJ · doi:10.1136/bmj.280.6228.1353 · Cited by 169
Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade
Jacobs, R. L., Rake, G. W., Fournier, D. C., CHILTON, R. J., Culver, W. G., & Beckmann, C. H. (1981) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(81)90170-6 · Cited by 152
Hypersensitivity Reactions to Cancer Chemotherapeutic Agents
Weiss, R. B., & Bruno, S. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-1-66 · Cited by 123
Self-citation
Cited by
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Self-citationGelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Paclitaxel and its formulations
Singla, A. K., Garg, A., & Aggarwal, D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00986-3 · Cited by 1,100
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947
Iron Oxide Nanoparticles for Sustained Delivery of Anticancer Agents
Jain, T. K., Morales, M. A., Sahoo, S. K., Leslie-Pelecky, D. L., & Labhasetwar, V. (2005) · Molecular Pharmaceutics · doi:10.1021/mp0500014 · Cited by 904
Wolinsky, J. B., Colson, Y. L., & Grinstaff, M. W. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.031 · Cited by 845
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
THE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Protein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Fonseca, C., Simões, S., & Gaspar, R. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00212-2 · Cited by 755
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734
Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention
Pai, V. B., & Nahata, M. C. (2000) · Drug Safety · doi:10.2165/00002018-200022040-00002 · Cited by 729
Allergy Diagnostic Testing: An Updated Practice Parameter
Bernstein, I. L., Li, J. T., Bernstein, D. I., Hamilton, R., Spector, S. L., Tan, R., Sicherer, S., Golden, D. B. K., Khan, D. A., Nicklas, R. A., et al. (2008) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)60305-5 · Cited by 723
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
Rowinsky, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.353 · Cited by 721
Shaker, M. S., Wallace, D. V., Golden, D. B. K., Oppenheimer, J., Bernstein, J. A., Campbell, R. L., Dinakar, C., Ellis, A., Greenhawt, M., Khan, D. A., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.01.017 · Cited by 715
Albumin-bound paclitaxel: a next-generation taxane
Gradishar, W. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1041 · Cited by 712
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695
Green, M. R., Manikhas, G. M., Orlov, S., Afanasyev, B., Makhson, A. M., Bhar, P., & Hawkins, M. J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl104 · Cited by 667
Chemistry and Biology of Taxol
Nicolaou, K. C., Dai, W., & Guy, R. K. (1994) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199400151 · Cited by 623
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation
Danhier, F., Lecouturier, N., Vroman, B., Jérôme, C., Marchand-Brynaert, J., Feron, O., & Préat, V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.09.086 · Cited by 616
Castells, M. C., Tennant, N. M., Sloane, D. E., Ida Hsu, F., Barrett, N. A., Hong, D. I., Laidlaw, T. M., Legere, H. J., Nallamshetty, S. N., Palis, R. I., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.02.044 · Cited by 600
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Emerging use of nanoparticles in diagnosis and treatment of breast cancer
Yezhelyev, M. V., Gao, X., Xing, Y., Al-Hajj, A., Nie, S., & O'Regan, R. M. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70793-8 · Cited by 577
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics
Vangijzegem, T., Stanicki, D., & Laurent, S. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1554647 · Cited by 548
Paclitaxel: a review of adverse toxicities and novel delivery strategies
Marupudi, N. I., Han, J. E., Li, K. W., Renard, V. M., Tyler, B. M., & Brem, H. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.5.609 · Cited by 510
Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 504
Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles
Matsumura, Y., & Kataoka, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01103.x · Cited by 501
PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
Grossen, P., Witzigmann, D., Sieber, S., & Huwyler, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.028 · Cited by 496
Management and Preparedness for Infusion and Hypersensitivity Reactions
Lenz, H.-J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-601 · Cited by 479
Stimuli‐Responsive Polymersomes as Nanocarriers for Drug and Gene Delivery
Onaca, O., Enea, R., Hughes, D. W., & Meier, W. (2009) · Macromolecular Bioscience · doi:10.1002/mabi.200800248 · Cited by 465
Wei, Z., Hao, J., Yuan, S., Li, Y., Juan, W., Sha, X., & Fang, X. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.030 · Cited by 427
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., & Sartorius, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1692 · Cited by 426
Szebeni, J., Muggia, F., Gabizon, A., & Barenholz, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.017 · Cited by 423
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Feng, S.-S., & Huang, G. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00364-3 · Cited by 398
Spencer, C. M., & Faulds, D. (1994) · Drugs · doi:10.2165/00003495-199448050-00009 · Cited by 396
Cardiac disturbances during the administration of taxol.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1704 · Cited by 395
Self-citationRecent progress in biomedical applications of pluronic (PF127): Pharmaceutical perspectives
Akash, M. S. H., & Rehman, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.032 · Cited by 394
Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation
Yang, T., Cui, F.-D., Choi, M.-K., Cho, J.-W., Chung, S.-J., Shim, C.-K., & Kim, D.-D. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.02.011 · Cited by 385
Xin, H., Jiang, X., Gu, J., Sha, X., Chen, L., Law, K., Chen, Y., Wang, X., Jiang, Y., & Fang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.044 · Cited by 384
Immunological and Toxicological Considerations for the Design of Liposomes
Inglut, C. T., Sorrin, A. J., Kuruppu, T., Vig, S., Cicalo, J., Ahmad, H., & Huang, H.-C. (2020) · Nanomaterials · doi:10.3390/nano10020190 · Cited by 371
Zhang, W., Shi, Y., Chen, Y., Ye, J., Sha, X., & Fang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.039 · Cited by 368
Photodynamic nanomedicine in the treatment of solid tumors: Perspectives and challenges
Master, A., Livingston, M., & Sen Gupta, A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.02.020 · Cited by 367
Liposomal paclitaxel formulations
Koudelka, Š., & Turánek, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.006 · Cited by 366
Clinical Features of Hypersensitivity Reactions to Carboplatin
Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., & Belinson, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1141 · Cited by 365
Feng, S.-S., & Chien, S. (2003) · Chemical Engineering Science · doi:10.1016/s0009-2509(03)00234-3 · Cited by 364
Novel formulations of taxanes: a review. Old wine in a new bottle?
Hennenfent, K. L., & Govindan, R. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj100 · Cited by 345
Szebeni, J., Alving, C. R., & Muggia, F. M. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.4.300 · Cited by 341
Crosasso, P., Ceruti, M., Brusa, P., Arpicco, S., Dosio, F., & Cattel, L. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00166-2 · Cited by 338
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel
Danhier, F., Vroman, B., Lecouturier, N., Crokart, N., Pourcelle, V., Freichels, H., Jérôme, C., Marchand-Brynaert, J., Feron, O., & Préat, V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.08.011 · Cited by 335
Zhang, J. A., Anyarambhatla, G., Ma, L., Ugwu, S., Xuan, T., Sardone, T., & Ahmad, I. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.06.009 · Cited by 334
Sahoo, S. K., Ma, W., & Labhasetwar, V. (2004) · International Journal of Cancer · doi:10.1002/ijc.20405 · Cited by 327
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
Rowinsky, E. K., & Donehower, R. C. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90086-2 · Cited by 321
Self-citationPhase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J. L., Rubin, S., Curtin, J., Barakat, R., & Phillips, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.9.1485 · Cited by 313
Nanotechnological carriers for cancer chemotherapy: The state of the art
Estanqueiro, M., Amaral, M. H., Conceição, J., & Sousa Lobo, J. M. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.12.041 · Cited by 298
Mucocutaneous reactions to chemotherapy
Susser, W. S., Whitaker-Worth, D. L., & Grant-Kels, J. M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70488-3 · Cited by 294
Role of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Cannistra, S. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292108 · Cited by 291
Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603855 · Cited by 290
Liggins, R. T., & Burt, H. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00016-9 · Cited by 286
Nyman, D. W., Campbell, K. J., Hersh, E., Long, K., Richardson, K., Trieu, V., Desai, N., Hawkins, M. J., & Von Hoff, D. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6148 · Cited by 286
Self-citationTaxanes: A New Class of Antitumor Agents
Huizing, M. T., Misser, V. H. S., Pieters, R. C., ten Bokkel Huinink, W. W., Veenhof, C. H. N., Vermorken, J. B., Pinedo, H. M., & Beijnen, J. H. (1995) · Cancer Investigation · doi:10.3109/07357909509031919 · Cited by 285
The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®)
Pazdur, R., Kudelka, A. P., Kavanagh, J. J., Cohen, P. R., & Raber, M. N. (1993) · Cancer Treatment Reviews · doi:10.1016/0305-7372(93)90010-o · Cited by 278
Poly (amino acid) micelle nanocarriers in preclinical and clinical studies
Matsumura, Y. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.010 · Cited by 275
Ibrahim, N. K., Samuels, B., Page, R., Doval, D., Patel, K. M., Rao, S. C., Nair, M. K., Bhar, P., Desai, N., & Hortobagyi, G. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.013 · Cited by 267
Hyaluronic Acid Bioconjugates for the Delivery of Bioactive Molecules
Mero, A., & Campisi, M. (2014) · Polymers · doi:10.3390/polym6020346 · Cited by 264
Einzig, A. I., Wiernik, P. H., Sasloff, J., Runowicz, C. D., & Goldberg, G. L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1748 · Cited by 263
Self-citationHyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer
Yang, X.-Y., Li, Y.-X., Li, M., Zhang, L., Feng, L.-X., & Zhang, N. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.07.002 · Cited by 262
Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy
Lu, Z., Yeh, T.-K., Tsai, M., Au, J. L.-S., & Wientjes, M. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1443 · Cited by 256
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
Kundranda, M., & Niu, J. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s88023 · Cited by 255
Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs
Shin, H.-C., Alani, A. W. G., Rao, D. A., Rockich, N. C., & Kwon, G. S. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.024 · Cited by 243
Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9709-2 · Cited by 237
He, Z., Wan, X., Schulz, A., Bludau, H., Dobrovolskaia, M. A., Stern, S. T., Montgomery, S. A., Yuan, H., Li, Z., Alakhova, D., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.002 · Cited by 197
Engineered in-situ depot-forming hydrogels for intratumoral drug delivery
Fakhari, A., & Anand Subramony, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.014 · Cited by 164
Potential of Chitosan and its derivatives for controlled drug release applications – A review
Safdar, R., Omar, A. A., Arunagiri, A., Regupathi, I., & Thanabalan, M. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.10.020 · Cited by 147
Drug-induced morphology switch in drug delivery systems based on poly(2-oxazoline)s
Schulz, A., Jaksch, S., Schubel, R., Wegener, E., Di, Z., Han, Y., Meister, A., Kressler, J., Kabanov, A. V., Luxenhofer, R., et al. (2014) · ACS Nano · doi:10.1021/nn406388t · Cited by 142
Han, Y., He, Z., Schulz, A., Bronich, T. K., Jordan, R., Luxenhofer, R., & Kabanov, A. V. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300159u · Cited by 125
A7RC peptide modified paclitaxel liposomes dually target breast cancer
Cao, J., Wang, R., Gao, N., Li, M., Tian, X., Yang, W., Ruan, Y., Zhou, C., Wang, G., Liu, X., et al. (2015) · Biomaterials Science · doi:10.1039/c5bm00161g · Cited by 93
Liu, S. Q., Tong, Y. W., & Yang, Y. Y. (2005) · Molecular BioSystems · doi:10.1039/b501756b · Cited by 74
Zhang, C., Zhang, X., Zhao, W., Zeng, C., Li, W., Li, B., Luo, X., Li, J., Jiang, J., Deng, B., et al. (2019) · Nano Research · doi:10.1007/s12274-019-2308-9 · Cited by 61
Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0827-2 · Cited by 47
Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer
Wadler, S., Tenteromano, L., Cazenave, L., Sparano, J. A., Greenwald, E. S., Rozenblit, A., Kaleya, R., & Wiernik, P. H. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685088 · Cited by 43
Self-citationPreparation, characterization, and pharmacokinetics of liposomal docetaxel for oral administration
Kim, J. H., Shin, D. H., & Kim, J.-S. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1046-y · Cited by 37
Metadata
- Authors
- Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B.
- Venue
- Journal of Clinical Oncology
- Published
- 1990-07
- Volume
- 8
- Issue
- 7
- Pages
- 1263-1268
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1935541780
- Cited by
- 1,174
- References
- 16
- FWCI
- 11.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.